US Patent

US12065432 — Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid

Method of Use · Assigned to Vertex Pharmaceuticals Inc · Expires 2028-12-04 · 3y remaining

Vulnerability score 71/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a specific crystalline form of a drug and methods of using it in pharmaceutical compositions for treatment.

USPTO Abstract

The present invention relates to a substantially crystalline and free solid state form of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Form I), pharmaceutical compositions thereof, and methods of treatment therewith.

Drugs covered by this patent

Kalydeco (IVACAFTOR) · Vertex Pharms Inc

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3983`	—	Kalydeco
`U-3983`	—	Kalydeco
`U-3984`	—	Kalydeco
`U-3983`	—	Kalydeco
`U-3984`	—	Kalydeco

Patent Metadata

Patent number: US12065432
Jurisdiction: US
Classification: Method of Use
Expires: 2028-12-04
Drug substance claim: No
Drug product claim: No
Assignee: Vertex Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.